Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria (Q30458193)

21 June 2017

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria (English)

1 reference

21 June 2017

1 reference

0 references

20

0 references

Bruno Dubois

1

Bruno Dubois

0 references

Sebastiaan Engelborghs

13

Sebastiaan Engelborghs

1 reference

21 June 2017

Leonardo C de Souza

27

0 references

Randall J. Bateman

Randall Bateman

10

0 references

Howard Feldman

Howard H Feldman

2

0 references

José Luis Molinuevo

José Luis Molinuevo

5

0 references

Giovanni B. Frisoni

Giovanni B Frisoni

14

0 references

Yaakov Stern

Yaakov Stern

31

0 references

Philip Scheltens

32

Philip Scheltens

1 reference

21 June 2017

4

Harald Hampel

1 reference

21 June 2017

6

Kaj Blennow

1 reference

21 June 2017

Sebastian Crutch

12

0 references

Agneta Nordberg

Agneta Nordberg

19

0 references

Steven T. DeKosky

Steven T DeKosky

7

0 references

Bruno Vellas

28

Bruno Vellas

1 reference

21 June 2017

33

Jeffrey L Cummings

1 reference

21 June 2017

21

Gil Rabinovici

1 reference

21 June 2017

9

Dennis Selkoe

1 reference

21 June 2017

15

Nick C Fox

1 reference

21 June 2017

26

Stéphane Epelbaum

1 reference

21 June 2017

17

Marie-Odile Habert

1 reference

21 June 2017

30

Lon Schneider

1 reference

21 June 2017

23

Christopher Rowe

1 reference

21 June 2017

16

Douglas Galasko

1 reference

21 June 2017

11

Stefano Cappa

1 reference

21 June 2017

24

Stephen Salloway

1 reference

21 June 2017

8

Serge Gauthier

1 reference

21 June 2017

18

Gregory A Jicha

1 reference

21 June 2017

Claudia Jacova

3

1 reference

21 June 2017

Philippe Robert

22

1 reference

21 June 2017

Marie Sarazin

25

1 reference

21 June 2017

Pieter J Visser

29

1 reference

21 June 2017

1 June 2014

1 reference

21 June 2017

1 reference

21 June 2017

13

1 reference

21 June 2017

614-629

1 reference

21 June 2017

6

1 reference

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Amnestic MCI or prodromal Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Explicit memory in frontotemporal dementia: the role of medial temporal atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer's, Parkinson's, and Huntington's diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Verbal memory performance of patients with a first depressive episode and patients with unipolar and bipolar recurrent depression.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Memory function in normal aging.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

The amnestic syndrome of hippocampal type in Alzheimer's disease: an MRI study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Revising the definition of Alzheimer's disease: a new lexicon.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Neuropathology of older persons without cognitive impairment from two community-based studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Neuropathology of cognitively normal elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Preclinical AD Workgroup staging: pathological correlates and potential challenges.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Retrospective evaluation of revised criteria for the diagnosis of Alzheimer's disease using a cohort with post-mortem diagnosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Imaging markers for Alzheimer disease: which vs how

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

How preserved is episodic memory in behavioral variant frontotemporal dementia?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Screening for dementia by memory testing

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Screening for predementia AD: time-dependent operating characteristics of episodic memory tests

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cognitively preserved subjects with transitional cerebrospinal fluid ß-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Alzheimer disease: can the exam predict the pathology?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Measuring cognitive change in subjects with prodromal Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Verbal cued recall as a predictor of conversion to Alzheimer's disease in Mild Cognitive Impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Predicting rapid clinical progression in amnestic mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Comparing predictors of conversion and decline in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Recall and recognition of verbal paired associates in early Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Using the Rey Auditory Verbal Learning Test (RAVLT) to differentiate alzheimer's dementia and behavioural variant fronto-temporal dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

A brief neuropsychological assessment for the differential diagnosis between frontotemporal dementia and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Evaluation of visual recognition memory in MCI patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Identification of subgroups in amnestic mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Topographical short-term memory differentiates Alzheimer's disease from frontotemporal lobar degeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Short-term memory binding is impaired in AD but not in non-AD dementias.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Visual short-term memory binding deficits in familial Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Added diagnostic value of CSF biomarkers in differential dementia diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

CSF markers for incipient Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

CSF biomarker variability in the Alzheimer's Association quality control program

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Biochemical markers in persons with preclinical familial Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

CSF biomarkers in frontotemporal lobar degeneration with known pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Research and standardization in Alzheimer's trials: reaching international consensus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

[(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

PET imaging of amyloid deposition in patients with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Clinical amyloid imaging in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Frequent amyloid deposition without significant cognitive impairment among the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

1 reference

7 January 2021

Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Relationships between biomarkers in aging and dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cognitive phenotypes in Alzheimer's disease and genetic risk.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Posterior cortical atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

The paradox of syndromic diversity in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Progressive biparietal atrophy: an atypical presentation of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

The logopenic variant of primary progressive aphasia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Does executive impairment define a frontal variant of Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Differentiating the frontal variant of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Focal cortical presentations of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Clinical and pathological evidence for a frontal variant of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Clinicopathologic differences among patients with behavioral variant frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Quantitative neuropathologic analysis of Pick's disease cases: cortical distribution of Pick bodies and coexistence with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Theoretical exploration of the neural bases of behavioural disinhibition, apathy and executive dysfunction in preclinical Alzheimer's disease in people with Down's syndrome: potential involvement of multiple frontal-subcortical neuronal circuits.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Prevalence of dementia disorders in the oldest-old: an autopsy study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Late and early onset dementia: what is the role of vascular factors? A retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cognitive impairment no dementia - neuropsychological and neuroimaging characterization of an amnestic subgroup.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Verbal and visuospatial deficits in dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Differences exist in the cognitive profile of mild Alzheimer's disease and subcortical ischemic vascular dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Clinical trials in predementia stages of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Testing the right target and right drug at the right stage

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Distinct functional activity of the precuneus and posterior cingulate cortex during encoding in the preclinical stage of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Are subjective cognitive complaints a risk factor for dementia?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Subjective cognitive complaints and amyloid burden in cognitively normal older individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Indicators of amyloid burden in a population-based study of cognitively normal elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Support vector machine-based classification of Alzheimer's disease from whole-brain anatomical MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Amyloid + activation = Alzheimer's?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Neuroimaging in Alzheimer disease: an evidence-based review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Impairment and compensation coexist in amnestic MCI default mode network.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Modifiable factors that alter the size of the hippocampus with ageing

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Is hippocampal volume a good marker to differentiate Alzheimer's disease from frontotemporal dementia?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

The topography of grey matter involvement in early and late onset Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Reliability of cerebral measures in repeated examinations with magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Longitudinal change of biomarkers in cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Brain imaging in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

PET translates neurophysiology into images: A review to stimulate a network between neuroimaging and basic research

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Cognitive reserve in ageing and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden--regulatory considerations by European Medicines Agency focusing in improving be

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Distinct profiles of brain and cognitive changes in the very old with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Focal temporal lobe dysfunction in probable Alzheimer's disease predicts a slow rate of cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Brain perfusion abnormalities in Alzheimer's disease: comparison between patients with focal temporal lobe dysfunction and patients with diffuse cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Probable Alzheimer's disease patients presenting as "focal temporal lobe dysfunction" show a slow rate of cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Age and diagnostic performance of Alzheimer disease CSF biomarkers.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Age, neuropathology, and dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Rates of decline in Alzheimer disease decrease with age.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Risk factors for Alzheimer disease: aging beyond age?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Relevance of outcome measures in different cultural groups--does one size fit all?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

The Pietà study: epidemiological investigation on successful brain aging in Caeté (MG), Brazil. Methods and baseline cohort characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

Emotional and psychological implications of early AD diagnosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970090-0

7 January 2021

10.1016/S1474-4422(14)70090-0

Identifiers

DOI

1 reference

21 June 2017

1 reference